Animal Histopathology Core Faciiity The UNC Lineberger Comprehensive Cancer Center has a major strategic commitment to mouse models of human disease. Multiple faculty use these models in their research funded to probe cancer etiology and biology, and increasingly to test therapeutic efficacy of novel compounds and multimodality therapies. An important endpoints of animal studies are pathologic evaluation and in situ molecular analysis;these help to determine therapeutic efficacy, potential toxicity, and disease pathogenesis. The goal of the LCCC Animal Histopathology Core (AHC) is to provide high quality, affordable histology and molecular pathology support to the UNC biomedical research community. The AHC adds value through a convenient campus location, customizable services, subsidized pricing, and access to board-certified veterinary pathologists. Major services include tissue embedding and sectioning (frozen and paraffin), routine and special stains, and consultation on animal study design, tissue collection and pathologic interpretation. In 2008 all of the basic histology equipment was upgraded to increase throughput and automation;in 2009 a third FTE histotechnologist and an automated immunostainer were added. Members receive priority access and a 50% or greater discount for most services. The Faculty Director is Arlin Rogers, an ACVP-certified pathologist with more than 15 years of experience using animal models in research. In addition to his independent studies on liver carcinogenesis, he has directed animal histopathology cores for the past seven years. Facility Director Janice Weaver is a highly skilled histotechnologist and laboratory administrator. Under current leadership, annual productivity increased 61% since the last competing renewal. In 2009, the Core served 52 member users representing 7 research programs. For 2010, the Core requests $121,382 in CCSG funds, representing 27% of its operating costs;88% of procedures were performed for cancer center members last year. Future plans include fee-for service immunohistochemistry and in situ hybridization, maintenance of rapid turnaround times and excellent quality of routine submissions, and support for UNC animal research initiatives including the Mouse Phase I Unit and the Collaborative Cross.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-38
Application #
8594144
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$192,980
Indirect Cost
$66,181
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Joseph, Sarah B; Arrildt, Kathryn T; Sturdevant, Christa B et al. (2015) HIV-1 target cells in the CNS. J Neurovirol 21:276-89
Sikov, William M; Berry, Donald A; Perou, Charles M et al. (2015) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (A J Clin Oncol 33:13-21
Blazer, Marlo; Wu, Christina; Goldberg, Richard M et al. (2015) Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol 22:1153-9
Knight, E R W; Patel, E Y; Flowers, C A et al. (2015) ASC deficiency suppresses proliferation and prevents medulloblastoma incidence. Oncogene 34:394-402
Dellon, Evan S; Speck, Olga; Woodward, Kimberly et al. (2015) Distribution and variability of esophageal eosinophilia in patients undergoing upper endoscopy. Mod Pathol 28:383-90
Qi, Qibin; Kilpeläinen, Tuomas O; Downer, Mary K et al. (2014) FTO genetic variants, dietary intake and body mass index: insights from 177,330 individuals. Hum Mol Genet 23:6961-72
Jha, Deepak Kumar; Strahl, Brian D (2014) An RNA polymerase II-coupled function for histone H3K36 methylation in checkpoint activation and DSB repair. Nat Commun 5:3965
Guo, Shutao; Lin, C Michael; Xu, Zhenghong et al. (2014) Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano 8:4996-5009
Clark, Martha A; Goheen, Morgan M; Spidale, Nicholas A et al. (2014) RBC barcoding allows for the study of erythrocyte population dynamics and P. falciparum merozoite invasion. PLoS One 9:e101041
Zhang, Weihe; DeRyckere, Deborah; Hunter, Debra et al. (2014) UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. J Med Chem 57:7031-41

Showing the most recent 10 out of 292 publications